Percorrer por autor "Gomes, Andreia"
A mostrar 1 - 4 de 4
Resultados por página
Opções de ordenação
- De novo human angiotensin - converting enzyme 2 Decoy NL-CVX1 protects mice from severe disease after severe acute respiratory syndrome coronavirus 2 infectionPublication . Rebelo, Maria; Tang, Cong; Coelho, Ana R.; Labão-Almeida, Carlos; Schneider, Matthias M.; Tatalick, Laurie; Ruivo, Pedro; de Miranda, Marta Pires; Gomes, Andreia; Carvalho, Tânia; Walker, Matthew J.; Ausserwoeger, Hannes; Simas, J. Pedro; Veldhoen, Marc; Knowles, Tuomas P. J.; Silva, Daniel Adriano; Shoultz, David; Bernardes, Gonçalo J. L.The emergence of novel variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) underscores the need to investigate alternative approaches to prevent infection and treat patients with coronavirus disease 2019. Here, we report the preclinical efficacy of NL-CVX1, a de novo decoy that blocks virus entry into cells by binding with nanomolar affinity and high specificity to the receptor-binding domain of the SARS-CoV-2 spike protein. Using a transgenic mouse model of SARS-CoV-2 infection, we showed that a single prophylactic intranasal dose of NL-CVX1 conferred complete protection from severe disease following SARS-CoV-2 infection. Multiple therapeutic administrations of NL-CVX1 also protected mice from succumbing to infection. Finally, we showed that infected mice treated with NL-CVX1 developed both anti-SARS-CoV-2 antibodies and memory T cells and were protected against reinfection a month after treatment. Overall, these observations suggest NL-CVX1 is a promising therapeutic candidate for preventing and treating severe SARS-CoV-2 infections.
- The effectiveness of the gut microbiota modulation on ADHD in adults: a systematic reviewPublication . Gomes, Andreia; Siopa, Carlos; Pestana, Pedro Câmara; Novais, FilipaPurpose of Review: To critically assess the effectiveness of gut microbiota modulation (GMM) as a complementary approach for managing Attention Deficit Hyperactivity Disorder (ADHD) in adults. Methods: A systematic review was conducted following the JBI Manual for Evidence Synthesis, with searches in PubMed, Web of Science, Cochrane Database, ClinicalTrials.gov, EMBASE/Ovid, and APA PsycInfo. Results: Among 3,591 identified studies, only three randomized controlled trials met the inclusion criteria. One study reported improvements in inattention, while another found benefits in hyperactivity. Additionally, synbiotics and probiotics showed positive effects on emotional dysregulation, inflammatory markers, and gastrointestinal symptoms, reinforcing the link between gut microbiota and ADHD. However, the evidence remains inconsistent, and the studies are heterogeneous in methodology and outcomes. Summary: This review highlights the potential of GMM, particularly to enhance the management of refractory ADHD or for patients who experience significant side effects from conventional treatments. However, due to the very limited evidence, further high-quality, standardized trials are needed to determine its effectiveness, identify optimal bacterial strains and dosages, and develop more personalized treatment approaches, for better patient outcomes and functioning.
- Escala de orientações gerais para objetivos de desempenho: estudos de adaptação para o ensino secundárioPublication . Gomes, Andreia; Azevedo, Ângela Sá; Dias, Paulo César; Guimarães, Teresa; Lima, Isabel; Salgado, AnaEste trabalho pretende apresentar os resultados de adaptação portuguesa da Escala de Orientações Gerais para Objetivos de Desempenho (EOGOD; McInerney & Yeung, 2000). Trata-se de instrumento de medida com cinco escalas de motivação: Valorização da Motivação, Motivação Geral, Orientação para a Mestria, Orientação para o Desempenho e Orientação Social. Para a sua adaptação, foi realizada análise fatorial exploratória e confirmatória e análise de consistência interna a partir de dois grupos, de 617 e 418 estudantes do Ensino Secundário. Os dados obtidos permitiram encontrar uma solução com boas propriedades psicométricas, seja em termos de validade como fiabilidade aceitáveis, assim como diferenças em função do género e relação com a idade e escolaridade. Os resultados são discutidos e apresentadas sugestões.
- Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onsetPublication . Figueiredo-Campos, Patrícia; Blankenhaus, Birte; Mota, Catarina; Gomes, Andreia; Serrano, Marta; Ariotti, Silvia; Costa, Catarina; Nunes-Cabaço, Helena; Mendes, António M.; Gaspar, Pedro; Pereira-Santos, M. Conceição; Rodrigues, Fabiana; Condeço, Jorge; Escoval, M. Antonia; Santos, Matilde; Ramirez, Mario; Melo-Cristino, José; Simas, J. Pedro; Vasconcelos, Eugenia; Afonso, Ângela; Veldhoen, MarcSARS-CoV-2 has emerged as a human pathogen, causing clinical signs, from fever to pneumonia—COVID-19—but may remain mild or asymptomatic. To understand the continuing spread of the virus, to detect those who are and were infected, and to follow the immune response longitudinally, reliable and robust assays for SARS-CoV-2 detection and immunological monitoring are needed. We quantified IgM, IgG, and IgA antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) or the Spike (S) protein over a period of 6 months following COVID-19 onset. We report the detailed setup to monitor the humoral immune response from over 300 COVID-19 hospital patients and healthcare workers, 2500 University staff, and 198 post-COVID-19 volunteers. Anti-SARS-CoV-2 antibody responses follow a classic pattern with a rapid increase within the first three weeks after symptoms. Although titres reduce subsequently, the ability to detect anti-SARS-CoV-2 IgG antibodies remained robust with confirmed neutralization activity for up to 6 months in a large proportion of previously virus-positive screened subjects. Our work provides detailed information for the assays used, facilitating further and longitudinal analysis of protective immunity to SARS-CoV-2. Importantly, it highlights a continued level of circulating neutralising antibodies in most people with confirmed SARS-CoV-2.